Olema Pharmaceuticals’ $240 Million Initial Public Offering

Davis Polk advised the representatives of the several underwriters in the offering.

Olema Oncology completed its $240 million initial public offering of 12,650,000 shares of common stock, at $19.00 per share (which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares). Olema’s common stock is listed on the Nasdaq Global Select Market under the symbol “OLMA.”

J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC acted as active joint book-running managers for the offering. Canaccord Genuity LLC also acted as a book-running manager.

Olema is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema is headquartered in San Francisco, California.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associates Ali DeGolia and Paula Gergen. The intellectual property and technology transactions team included partner David R. Bauer and associates S. Dream Montgomery and Daniel P. Kearney. The tax team included partner Po Sit and associate Tyler Scheiner. Counsel Marcie A. Goldstein provided FINRA advice. Associate J. Taylor Arabian provided 1940 Act advice.

Involved fees earner: Taylor Arabian – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Ali DeGolia – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Paula Gergen – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Daniel Kearney – Davis Polk & Wardwell; S. Dream Montgomery – Davis Polk & Wardwell; Tyler Scheiner – Davis Polk & Wardwell; Po Sit – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Canaccord Genuity; Cowen and Company; J.P. Morgan Securities LLC; Jefferies;

Print Friendly, PDF & Email

Author: Ambrogio Visconti